Overview

Phase II Trial for the Treatment of Relapsed Osteosarcoma

Status:
Terminated
Trial end date:
2019-01-07
Target enrollment:
Participant gender:
Summary
Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma
Phase:
Phase 2
Details
Lead Sponsor:
Italian Sarcoma Group
Treatments:
Docetaxel
Gemcitabine
Ifosfamide
Isophosphamide mustard